
Microglia are brain immune cells that maintain homeostasis and respond to injury, changing cell morphology to drive inflammation, migration, and phagocytosis. This study examined the role of the kinesin KIF21B in microglial activation, demonstrating for the first time its expression in microglial cells in two in vivo neuroinflammatory models: TBI (focal inflammation) and LPS administration (diffuse inflammation). While TBI provoked a significant increase in KIF21B/Iba1 colocalization in the tissue around the lesion exclusively in females, LPS administration did not alter KIF21B expression in either sex. Given the importance of cytoskeleton remodeling for microglial migration and phagocytosis, this work investigates whether KIF21B contributes to these actions. Downregulating KIF21B in primary cultured mouse microglia had sex-specific effects. In females, KIF21B silencing reduced both migratory capacity and phagocytosis of E. coli-coated spheres and neuronal debris. In males, it exacerbated migration and selectively increased neuronal debris phagocytosis, while E. coli-coated sphere uptake remained unaffected. These functional differences were accompanied by sex-dependent morphological alterations, quantified through area, circularity, Feret's diameter, and perimeter: KIF21B silencing blocked the transition to amoeboid morphology in females while inducing hyperpolarized elongation in males. Finally, LPS treatment increased KIF21B colocalization with microtubules and reduced its colocalization with F-actin in females, while neither interaction was significantly altered in males. Overall, the findings suggest that KIF21B regulates microglial function in a sex-dependent manner through its effects on cytoskeletal organization.
Overcoming remyelination failure is one of the main targets in therapeutic strategies for multiple sclerosis. This process requires the differentiation of oligodendrocyte precursor cells (OPCs) to mature myelinating oligodendrocytes (OLs), a process known to be controlled by thyroid hormone, nuclear receptors, and sonic hedgehog (SHH). Retinoid X receptor gamma (RXRg) is one of the nuclear receptors acting as a positive regulator of remyelination, but little is known about its mechanisms of function. Using transcriptomic and pharmacological analysis of primary neural stem cell-derived OPCs, we show that RXRg is involved in the induction of the thyroid hormone-driven differentiation process and in refining it toward an oligodendrogenic cell fate. RXRg also emerged as an important negative modulator of SHH expression and signaling, as Shh and additional genes from this pathway were found to be strongly upregulated in Rxrg -/- OPCs. An inhibition of SHH signaling by cyclopamine or GANT61 entirely normalized the differentiation deficit of Rxrg -/- OPCs, but also myelination of newly generated Rxrg -/- OLs. Such data indicate a key role of SHH hyperactivity in the oligodendrogenesis block associated with the absence of RXRg. Importantly, hyperactivation of the SHH pathway by purmorphamine or SAG inhibited the oligodendrogenesis and myelination potential of wild-type OPCs, indicating that SHH hyperactivity can also be a sufficient factor to block OPC differentiation. These results point to RXRg as an important regulator of SHH pathway signaling and underline the need of an optimal, fine-tuning of SHH signaling to assure successful oligodendrogenesis.
Background Stroke remains a leading global cause of mortality and disability, with optimal outcomes dependent on rapid risk identification, precise acute management, tailored interventions, and sustained rehabilitation. Digital twins, which are dynamic computational replicas of individual patients integrating multimodal data and mechanistic models, represent an innovative approach to simulating disease trajectories and treatment responses before real world implementation. Aim This narrative review synthesises current evidence on digital twin applications across the stroke care continuum, examining their role in risk prediction, acute decision support, clinical trial optimisation, intensive care monitoring, and personalised neurorehabilitation. Method We explored publications from PubMed, Nature Portfolio journals, IEEE and ACM databases spanning 2021 to 2025, identifying relevant publications across technical, clinical, and implementation dimensions. Search terms combined “digital twin” with stroke-specific and enabling-technology terminology. The review integrates findings across technical, clinical, and implementation dimensions to provide a holistic perspective on this rapidly evolving field. Results Emerging evidence demonstrates feasibility and early clinical utility of digital twins across multiple stroke phases. Applications include atrial fibrillation related embolic risk stratification through patient specific left atrial modelling, imaging informed cerebrovascular hemodynamics for acute triage, disease digital twin generators for trial enrichment, and robotic rehabilitation systems with adaptive learning. However, most studies remain at preclinical or early pilot stages, with few meeting strict real-time digital twin criteria requiring bidirectional data flow and continuous updating. Conclusion Digital twins offer transformative potential for stroke care through personalised risk assessment, hyperacute decision support, and adaptive rehabilitation. Translation to routine practice requires rigorous prospective validation, standardised data models, robust governance frameworks, and demonstrated clinical utility across diverse populations. A clear translational roadmap, from current component technologies to fully closed-loop systems, is essential to guide investment and prioritise research.
Cortical demyelination is a critical contributor to progressive disease in multiple sclerosis (MS). The barriers to cortical remyelination following demyelination are not fully understood, and there are no remyelinating treatments for MS. We previously took advantage of the spatial and temporal resolution of longitudinal in vivo imaging to study cortical oligodendrocyte regeneration following cuprizone-induced demyelination and found that oligodendrocyte regeneration was impaired. In this study, we investigated whether cortical reactive microglia disrupt oligodendrocyte regeneration. To do so, we used a combination of in situ RNA and immunofluorescence labeling to characterize cortical microglia reactive states following cuprizone-mediated demyelination. We then depleted cortical microglia by administering a Csf1r inhibitor during the recovery period from cuprizone and quantified oligodendrocyte recovery. We found that following cortical demyelination, deep cortical microglia change morphology, downregulate homeostatic markers (P2RY12, TMEM119), and upregulate a marker (CD68) associated with activated macrophages. These reactive changes persisted through early recovery post-cuprizone but resolved by late recovery. Depleting cortical microglia post-cuprizone restored the baseline density of deep cortical ASPA+ oligodendrocytes at early and late recovery. There were also more deep cortical BCAS1+ differentiating oligodendrocytes at early recovery when microglia were depleted, suggesting that transient deep cortical reactive microglia impair oligodendrocyte differentiation following demyelinating injury. Together, we found that cortical microglia adopt spatially restricted reactive functions after demyelination and deep cortical reactive microglia transiently reduce differentiating oligodendrocytes. A potential therapeutic strategy for progressive MS could involve targeting transiently reactive microglia at the right time and place in cortical lesions to promote oligodendrocyte regeneration.
Oligodendrocytes, traditionally recognized for their role in central nervous system myelination, have emerged during the last decades as key participants maintaining brain homeostasis in response to metabolic demands and stress. In addition, injury to myelin prompts a regenerative response that leads to the formation of new myelin sheaths. However, the signals regulating effective remyelination by oligodendrocytes are still not completely understood. Here, we report that oligodendrocytes can internalize exogenous myelin both in vitro and in vivo, which leads to an increase in oligodendroglial lineage progression. RNA sequencing reveals that myelin debris alters the oligodendrocyte transcriptional profile, leading to the suppression of immune-related pathways and de novo cholesterol and fatty acid biosynthesis, while promoting lipid droplet formation for the storage and processing internalized myelin particles. In primary cultures, myelin exposure increases oligodendrocyte progenitor (OPC) proliferation and overall oligodendroglia lineage progression, accompanied by greater cellular complexity and a larger myelinated area per cell, without altering the relative OPC-to-mature oligodendrocyte ratio. Stereotaxic injection of fluorescent myelin into mouse cortex and zebrafish ventricles shows internalization by microglia and, to a lesser extent, by oligodendroglia. Notably, in the zebrafish model, ventricular injections of myelin also increase the number of ventral oligodendrocytes in the spinal cord, further supporting that myelin can promote lineage progression. These findings challenge the classical view that myelin debris intrinsically inhibits oligodendrocyte proliferation, suggesting instead that oligodendrocytes can use myelin to support self-renewal and maturation across vertebrate species, acting as a trophic factor in the absence of pathological cues.